Nader Sanai
Clinical trials sponsored by Nader Sanai, explained in plain language.
-
New hope for glioblastoma: targeted drug enters brain trial
Disease control Recruiting nowThis study is for people with a newly diagnosed, aggressive brain cancer called glioblastoma that has a specific genetic change (MTAP deletion). The trial tests an experimental drug, BGB-58067, designed to target cancer cells while sparing healthy ones. The goal is to see if the …
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New drug targets Hard-to-Treat brain tumors in early trial
Disease control Recruiting nowThis early-phase trial tests an investigational drug called risvutatug rezetecan (GSK5764227) in 15 people with recurrent grade 4 glioma or brain metastases. The drug is designed to seek out and attack tumor cells while sparing healthy tissue. The study first checks how much drug…
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated May 17, 2026 04:08 UTC
-
Could a cancer drug stop aggressive meningiomas?
Disease control Recruiting nowThis study tests an FDA-approved cancer drug, abemaciclib, for people with a newly diagnosed aggressive type of brain tumor called grade 3 meningioma. About 72 participants will receive either the drug or a placebo after standard radiation therapy, and neither they nor their doct…
Phase: PHASE2 • Sponsor: Nader Sanai • Aim: Disease control
Last updated May 17, 2026 04:01 UTC